Athira Pharma Inc
NASDAQ:ATHA

Watchlist Manager
Athira Pharma Inc Logo
Athira Pharma Inc
NASDAQ:ATHA
Watchlist
Price: 6.96 USD -8.06% Market Closed
Market Cap: 27.4m USD

Operating Margin
Athira Pharma Inc

0%
Current
0%
Average
6%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
0%
=
Operating Profit
-39.3m
/
Revenue
0

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
Athira Pharma Inc
NASDAQ:ATHA
27.4m USD N/A
US
Eli Lilly and Co
NYSE:LLY
1T USD
44%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
3%
US
Johnson & Johnson
NYSE:JNJ
498.9B USD
27%
CH
Roche Holding AG
SIX:ROG
261.4B CHF
34%
UK
AstraZeneca PLC
LSE:AZN
210.8B GBP
24%
CH
Novartis AG
SIX:NOVN
210.3B CHF
33%
US
Merck & Co Inc
NYSE:MRK
264.8B USD
38%
DK
Novo Nordisk A/S
CSE:NOVO B
1.5T DKK
42%
IE
Endo International PLC
LSE:0Y5F
213.9B USD
11%
US
Pfizer Inc
NYSE:PFE
143.2B USD
29%
No Stocks Found

Athira Pharma Inc
Glance View

Market Cap
27.4m USD
Industry
Pharmaceuticals

Athira Pharma, Inc. engages in the development of small molecules to restore neuronal health and stop neurodegeneration. The company is headquartered in Bothell, Washington and currently employs 63 full-time employees. The company went IPO on 2020-09-18. The firm is focused on developing small molecules to restore neuronal health and stop neurodegeneration. Its pipeline consists of both blood brain barrier (BBB) permeable and peripherally restricted drug candidates for the central nervous system (CNS), peripheral nervous system (PNS), and other indications. Its lead candidate, fosgonimeton (ATH-1017), is a subcutaneously administered, small molecule positive modulator of the hepatocyte growth factor/mesenchymal-epithelial transition factor (HGF/MET) system for CNS disorders. The company is also advancing potential drug candidates for neuropathic pain, amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases. Its neuropathic pain drug candidate, ATH-1020, completed a Phase I single ascending dose evaluation in healthy volunteers. Its ATH-1105 is a small molecule compound designed to be an orally available, once-daily treatment to enhance the HGF/MET system.

ATHA Intrinsic Value
HIDDEN
Show
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
0%
=
Operating Profit
-39.3m
/
Revenue
0
What is the Operating Margin of Athira Pharma Inc?

Based on Athira Pharma Inc's most recent financial statements, the company has Operating Margin of 0%.

Back to Top